Analysed ARBUTUS BIOPHARMA CORP (ABUS:NASDAQ) News Sources
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
13-05-2026
yahoo.com
Arbutus Biopharma (ABUS) Joins Russell Defensive Indexes And Exits Value Benchmarks
09-07-2026
yahoo.com
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
16-07-2026
yahoo.com
ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?
16-07-2026
stocktwits.com
Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances
17-07-2026
biopharmadive.com
Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?
11-08-2026
yahoo.com
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
21-08-2026
yahoo.com
What is the current price of ARBUTUS BIOPHARMA CORP (ABUS:NASDAQ)?
The current price of ARBUTUS BIOPHARMA CORP (ABUS:NASDAQ) is $5.19.
ARBUTUS BIOPHARMA CORP (ABUS:NASDAQ) absolute price change since previous trading day?
The absolute price change of ARBUTUS BIOPHARMA CORP (ABUS:NASDAQ) since the previous trading day is $0.
ARBUTUS BIOPHARMA CORP (ABUS:NASDAQ) percentage price change since previous trading day?
The percentage price change of ARBUTUS BIOPHARMA CORP (ABUS:NASDAQ) since the previous trading day is 0%.
What is the most recent average sentiment score for ARBUTUS BIOPHARMA CORP (ABUS:NASDAQ)?
The most recent average sentiment score for ARBUTUS BIOPHARMA CORP (ABUS:NASDAQ) is 61 out of 100.
What is the most recent average sentiment for ARBUTUS BIOPHARMA CORP (ABUS:NASDAQ)?
The most recent sentiment for ARBUTUS BIOPHARMA CORP (ABUS:NASDAQ) is .
SEC-8K** Filing Available For ARBUTUS BIOPHARMA CORP (ABUS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.